Imugene starts manufacture of KEY-Vaxx for trials

Company News

by Rachael Jones

Clinical stage immuno-oncology company Imugene (ASX:IMU) has formally commenced cGMP manufacture of the clinical batch of cancer vaccine KEY-Vaxx for the proposed Phase 1 PD-1 clinical trial, after successfully completing pilot studies.

US-based cGMP manufacturer AmbioPharm Inc. has been appointed.

APi is a full-service peptide manufacturing company headquartered in South Carolina, USA.

KEY-Vaxx is a B-cell peptide cancer vaccine which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and potentially produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range of cancers.

Shares in Imugene (ASX:IMU) closed 4.76 per cent higher to 2.2 cents.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.